Abrahams, E., Ginsburg, G. S., and Silver, M., “The Personalized Medicine Coalition: Goals and Strategies,” American Journal of PharmacoGenomics 5, no. 6 (2005): 345–355; Lewis, L. D., “Personalized Drug Therapy; The Genome, The Chip and the Physician,” British Journal of Clinical Pharmacology 60, no. 1 (2005): 1–4.CrossRefGoogle Scholar

U.S. Food and Drug Administration Center for Drug Evaluation and Research, Information for Healthcare Professionals: Carbamazepine (Marketed as Carbatrol, Equetro, Tegretol, and Generics) - FDA Alert, available at <http://www.fda.gov/cder/drug/InfoSheets/HCP/carbamazepineHCP.htm> (last visited June 23, 2008) [hereinafter cited as USDA); Dooren, J. C. and Goldstein, J., “Epilepsy Drug to Get Stronger Warning,” Wall Street Journal (Eastern Edition), December 13, 2007, at D4.+(last+visited+June+23,+2008)+[hereinafter+cited+as+USDA);+Dooren,+J.+C.+and+Goldstein,+J.,+“Epilepsy+Drug+to+Get+Stronger+Warning,”+Wall+Street+Journal+(Eastern+Edition),+December+13,+2007,+at+D4.>Google Scholar

Id. (USDA).Google Scholar

Alfirevic, A., Jorgensen, A. L., Williamson, P. R., Chadwick, D. W., Park, B. K., and Pirmohamed, M., “HLA-B Locus in Caucasian Patients with Carbamazepine Hypersensitivity,” Pharmacogenomics 7, no. 6 (2006): 813–818; Hung, S. I., Chung, W. H., Jee, S. H., Chen, W. C., Chang, Y. T., Lee, W. R., Hu, S. L., Wu, M. T., Chen, G. S., Wong, T. W., Hsiao, P. F., Chen, W. H., Shih, H. Y., Fang, W. H., Wei, C. Y., Lou, Y. H., Huang, Y. L., Lin, J. J., and Chen, Y. T., “Genetic Susceptibility to Carbamazepine-Induced Cutaneous Adverse Drug Reactions,” Pharmacogenetics and Genomics 16, no. 4 (2006): 297–306; Lonjou, C., Thomas, L., Borot, N., Ledger, N., de Toma, C., LeLouet, H., Graf, E., Schumacher, M., Hovnanian, A., Mockenhaupt, M., and Roujeau, J. C., “A Marker for Stevens-Johnson Syndrome…: Ethnicity Matters,” Pharmacogenomics Journal 6, no. 4 (2006): 265–268; Man, C. B. L., Kwan, P., Baum, L., Yu, E., Lau, K. M., Cheng, A. S. H., and Ng, M. H. L., “Association between HLA-B*1502 Allele and Antiepileptic Drug-Induced Cutaneous Reactions in Han Chinese,” Epilepsia 48, no. 5 (2007): 1015–1018; Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., Wu, J. Y., and Chen, Y. T., “Medical Genetics: A Marker for Stevens-Johnson Syndrome,” Nature 428, no. 6982 (2004): 486.CrossRefGoogle Scholar

See USDA, supra note 2.Google Scholar

See generally Veregin, H., ed., Goode's Atlas of Asia (New Jersey: John Wiley & Sons, 2004).Google Scholar

See USDA, supra note 2.Google Scholar

U.S. Food and Drug Administration, FDA News, FDA Approves BiDil Heart Failure Drug for Black Patients, available at <http://www.fda.gov/bbs/topics/news/2005/new01190.html> (last visited June 23, 2008).+(last+visited+June+23,+2008).>Google Scholar

Stewart, A., “Heart Drug's Racial Focus Proves a Liability Rather Than an Asset,” The Star Ledger, May 31, 2008, available at <http://www.nj.com/business/index.ssf/2008/05/heart_drugs_racial_focus_prove.html> (last visited June 23, 2008); Kahn, J., “How a Drug Becomes ‘Ethnic’: Law, Commerce, and the Production of Racial Categories in Medicine,” Yale Journal of Health Policy Law 4, no. 1 (2004): 1–46; Armstrong, D., “Home and Family: NitroMed Halts Sale of Drug,” Wall Street Journal (Eastern Edition), January 16, 2008, at D3.Google Scholar